YM155 Inhibits survivin-mediated survival, migration, and tumor growth in neuroblastoma
McClung HM, Zhao P, Smith L, Saulnier Sholler G. YM155 Inhibits survivin-mediated survival, migration, and tumor growth in neuroblastoma. Advances in Neuroblastoma Research (ANR) annual meeting June 2012, Toronto, ON.
A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of Cancer Therapy
Saulnier Sholler G, Ferguson W, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W, Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna [...]
Side population analysis and gene expression profiling identify Notch pathway genes in neuroblastoma
Cecilia M, Mendonça F, Newton T, Saulnier Sholler G, and Roberts S. Side population analysis and gene expression profiling identify Notch pathway genes in neuroblastoma April 2012 AACR Annual Meeting, Chicago, IL
Single tumor imaging with multiple antibodies targeting different antigens. Biotechniques
Sun Y, Shukla G, Pero SC, Currier E, Saulnier Sholler G, Krag D. Single tumor imaging with multiple antibodies targeting different antigens. Biotechniques. 2012 Apr;0(0):1-3.
Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention
Bachmann AS, Geerts D, Saulnier Sholler G: Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention, In: Pediatric Cancer, Volume 1, Neuroblastoma: Diagnosis, Therapy, and Prognosis, Ed. Hayat MA, Springer,[...]
AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport
Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma[...]
Phase I Trial of TPI 287 as a Single Agent and in Combination with Temozolomide (TMZ) in Patients with Refractory or Recurrent Neuroblastoma (NB) or Medulloblastoma (MB)
Saulnier Sholler G, Eslin D, Roberts W, Kaplan J, Bergendahl G, Higgins T, Ashikaga T, Lenox S, Silberman S, Ferguson W. Phase I Trial of TPI 287 as a Single Agent[...]
Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma
Koto K, Lescault P, Brard L, Kim K, Singh R, Bond J, Illenye S, Slavik M, Ashikaga T, Saulnier Sholler G. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma.[...]
A Pilot Trial Testing the Feasibility of using Molecular-Guided Therapy in Patients with Refractory or Recurrent Neuroblastoma
Saulnier Sholler G, Kahn J, Ferguson W, Bergendahl G, Currier E, Lenox S, Bond J, Merchant M, Roberts W, Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati[...]
Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro
Singh R, Dorf L, DeMartino A, Illenye S, Koto K, Ashikaga T, Kwang Kim K, Brard L, Saulnier Sholler G. Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal[...]